Urocortin (UCN), a member of the corticotrophin-releasing factor family, is expressed in heart, brain and gut. UCN has potent cardiostimulatory, cardioprotective, vasodilator and diuretic/natriuretic effects, and cardiac UCN expression is increased in heart failure (HF). In the present study, we investigated plasma levels of UCN in 119 patients with HF and 212 age-and gender-matched controls to clarify its relationship with gender and disease severity. UCN was elevated in HF [normal males, 19.5 (3.9-68.8) pmol/l and HF males, 50.2 (6.9-108.2) pmol/l, P < 0.0005; normal females, 14.2 (3.9-53.5) pmol/l and HF females, 21.8 (3.9-112.5) pmol/l, P < 0.001; values are medians (range)]. The relative increase was greater in males than females (P < 0.03). UCN fell with increasing age, especially in HF patients (r s = − 0.56, P < 0.0005) and with increasing New York Heart Association (NYHA) class (r s = − 0.55, P < 0.0005). The fall in UCN levels with increasing NYHA class was reinforced by a significant correlation between UCN and ejection fraction (r s = 0.45, P < 0.0005) in HF patients. Although receiver operating characteristic (ROC) curves for diagnosis of all HF cases yielded an area under the curve (AUC) of 0.76, ROC AUCs for patients with early HF (NYHA class I and II) were better (0.91). ROC AUCs for logistic models incorporating N-terminal probrain natriuretic peptide (N-BNP) and UCN were better than either peptide alone. In conclusion, plasma UCN is elevated in HF, especially in its early stages. Its decline with increasing HF severity may expedite disease progression due to diminished cardioprotective/anti-inflammatory effects. UCN measurement may also complement N-BNP in the diagnosis of early HF.
INTRODUCTION
Neurohormonal activation is a consistent feature in systolic heart failure (HF; left ventricular systolic dysfunction) with complex interactions between endocrine systems. Urocortin (UCN), a novel cardiovascular peptide [1] , was so-called due to homology with fish urotensin and mammalian corticotrophin-releasing factor (CRF). It is localized mainly in heart and brain and acts on the CRF receptor type-2β [2] , which is expressed within heart, brain and gut, to elevate intracellular cAMP. UCN increases cardiac contractility and is a vasodilator [3] , an effect lacking in CRF receptor type-2β knockout mice [4] . In cardiac myocytes, UCN increases protein and atrial natriuretic peptide synthesis [5] . In cardiac cells which were not myocytes, UCN increases collagen and DNA synthesis [5] . This putative role in cardiac hypertrophy was confirmed in hearts from spontaneously hypertensive rats [5] . In addition, increased UCN was found in heart sections from HF patients [5] , suggesting a role in HF pathophysiology. UCN also has cardioprotective effects, since administration before or during simulated hypoxia/ischaemia both ex vivo and in vitro prevented cell death [6] , a process mediated through mitogenactivated protein kinase. Recent evidence from UCN administration to sheep with pacing-induced HF has shown increased cardiac contractility, reduced peripheral resistance and a natriuretic/diuretic effect [7] , suggesting a novel treatment for decompensated HF. Rademaker et al. [7] also demonstrated that the half-life of UCN was relatively long (1.2 to 20 h), and UCN also decreased levels of brain natriuretic peptide (BNP) [7] , a recognized marker of HF. These cardiovascular effects of UCN prompted us to investigate its plasma levels in humans with HF, firstly to understand whether UCN has a role in the pathophysiology of HF and, secondly, to assess its use and incremental value to an established marker [Nterminal proBNP (N-BNP)] as a diagnostic tool for HF.
METHODS

Plasma samples from subjects
Patients with HF were recruited from the Leicester Royal Infirmary clinics and wards. All had a clinical diagnosis of HF and echocardiographically confirmed left ventricular ejection fractions (LVEFs) 45 % (calculated using the methods of discs formula [8] on a Hewlett-Packard Sonos 5500 instrument). Normal controls were age-and gender-matched, were on no medication and had LVEF > 50 % (Table 1) . Informed consent was obtained from all subjects, and the study was approved by the Local Ethics Committee. After echocardiographic examination, 10 ml of blood was collected after 15 min bed rest into tubes containing EDTA and aprotinin. Plasma was stored at − 70
• C until assayed.
Assay of UCN
An antibody specific for UCN was obtained from Peninsular Laboratories. Biotinylated UCN purified on reverse-phase HPLC served as a tracer. A competitive immunoluminometric assay (ILMA) using C 18 -purified extracts of plasma was utilized, incubating 50 ng of the antibody with extracts or standards in 100 µl of assay buffer, as described previously [9] . After 24 h of incubation at 4
• C, biotinylated UCN tracer was added (250 fmol/well). ELISA plates coated with anti-(rabbit IgG) sera (Sigma) were used to recover immunoprecipitates. Following washes and incubation with streptavidin labelled with methyl-acridinium ester [9] , chemiluminescence was used as described previously [9] . Intra-and inter-assay coefficients of variation were 1.8 and 8.0 % respectively, with no cross-reactivity for CRF or urotensin. The lower limit of detection was 3.9 pmol/l. During C 18 extraction of plasma, the specimen was acidified with 1 % trifluoroacetic acid, which will dissociate protein complexes in the plasma, and it is likely that total, rather than bound or free, UCN is measured in these extracts.
Assay of N-BNP
Unextracted plasma was assayed for N-BNP using a noncompetitive ILMA as described previously [10] .
Statistical analysis
Statistical analyses were performed on SPSS Version 11. Spearman's correlation (r s ) values are reported. Posthoc comparisons were with Tukey's test for multiple comparisons. The univariate General Linear Model (GLM) procedure (SPSS) was used to examine independent effects and interactions of factors and covariates on UCN levels. Logistic regression analysis was performed for the different peptides for prediction of HF as the dependent variable. Comparison of areas under the receiver operating characteristic (ROC) curves (AUCs) was also performed [11] .
RESULTS
Figure 1(A) shows a standard curve for the UCN ILMA, showing competitive displacement of the biotinylated UCN tracer by unlabelled UCN. Two concentrated plasma extracts from HF patients were diluted in 2-fold steps, demonstrating parallelism with the UCN standard curve.
The characteristics of the normal and HF patients, who were well matched for age and gender, are shown in Table 1 . None of the normal controls had a past medical history of hypertension or diabetes, whereas 26.9 % of HF patients had hypertension and 11.8 % had diabetes. Plasma UCN was elevated in HF patients (Table 1) . In a univariate analysis, age correlated inversely with plasma UCN (r s = − 0.25, P < 0.0005), particularly in the HF patients (r s = − 0.56, P < 0.0005), but not in the normal controls (r s = − 0.06, not significant). Using the GLM procedure to compare UCN levels with age as a covariate and the presence of HF and gender as factors, a model accounting for an r 2 of 0.34 (P < 0.0005) was constructed with age (P < 0.0005), presence of HF (P < 0.0005) and gender (P < 0.0005) as significant factors. The relative increase was greater in males than females (P < 0.03). Although UCN levels were not different between normal males and females, males with HF had higher levels than females ( Figure 1B) . Analysis of levels of UCN in HF patients with the GLM procedure yielded an r 2 of 0.42 (P < 0.0005) with age (P < 0.006), gender (P < 0.04) and New York Heart Association (NYHA) class (P < 0.0005) as significant factors. There was no interaction of gender with NYHA class. Thus UCN levels fell with increasing NYHA class ( Figure 1C ) in both males and females. Posthoc comparisons of UCN levels reported differences between NYHA class I and class III or IV (P < 0.006 and P < 0.001 respectively) and between NYHA class II and class III or IV (P < 0.002 and P < 0.0005 respectively). Figure 1(D) , with older patients having lower plasma UCN levels. Since the patients in NYHA class III and IV were older than those in NYHA class I and II, the patients in these categories were also age-matched with respective controls in order to compare the plasma UCN levels. The fall in UCN levels with increasing NYHA class was also reinforced by the finding of a significant relationship with LVEF. Plasma UCN levels were dependent on LVEF (expressed as quartiles; Figure 2A ; P < 0.003), the lowest levels being found in the lowest LVEF quartile compared with the 3rd and 4th highest
Figure 2 Level of UCN in HF patients according to quartiles of LVEF (A) and relationship of UCN with LVEF in HF patients (B)
quartiles (P < 0.018 and P < 0.004 respectively). The correlation between UCN and LVEF in the HF patients was direct (r s = 0.45, P < 0.0005; Figure 2B ), in contrast with the negative correlation between N-BNP and LVEF in the same group of patients (r s = − 0.45, P < 0.0005). A negative relationship between UCN and N-BNP was evident in the HF patients (r s = − 0.48, P < 0.0005).
The aetiology of HF had no significant influence on plasma UCN levels [45.9 (3.9-112.5) pmol/l for patients with ischaemic cardiomyopathy compared with 34.9 (3.9-108.2) pmol/l for patients with dilated cardiomyopathy; values are medians (range)]. A past medical history of hypertension or diabetes also had no significant influence on UCN levels [46.7 (3.9-112.5) pmol/l in patients without hypertension compared with 26.7 (3.9-91.9) pmol/l in patients with hypertension; 44.4 (3.9-112.5) pmol/l in patients without diabetes compared with 26.7 (3.9-79.6) pmol/l in patients with diabetes; values are medians (range)]. Odds ratios were 1.67 (P < 0.0005) and 2.66 (P < 0.0005) for a 50 % elevation of N-BNP and UCN levels respectively. The AUC of the ROC plotted from the predicted probabilities derived from this model was 0.96 (S.E.M., 0.01), significantly better than either N-BNP or UCN alone (P < 0.003 and < 0.0001 respectively; Figure 3 ). For the diagnosis of early HF (NYHA class I and II), ROC AUCs for UCN and N-BNP were not significantly different [0.91 (S.E.M., 0.02) compared with 0.84 (S.E.M., 0.03); Figure 3 ]. In a logistic regression model for diagnosis of early HF, UCN and N-BNP accounted for a Nagelkerke r 2 of 0.74 (P < 0.0005). Odds ratios were 1.48 (P < 0.0005) and 5.11 (P < 0.0005) for 50 % elevation of N-BNP and UCN levels respectively. The predicted probabilities from this logistic model for diagnosis of early HF with UCN and BNP yielded a ROC AUC of 0.96 (S.E.M., 0.01), significantly better than UCN (P < 0.003) or N-BNP (P < 0.0004) alone (Figure 3) . Table 2 shows the specificities, positive and negative predictive values and accuracy for the diagnosis of all HF and the early HF (NYHA class I and II) patients at a sensitivity of 90 %, with appropriate cut-off values for N-BNP, UCN and the probabilities of the respective logistic models with both peptides.
DISCUSSION
UCN is a newly described peptide belonging to the CRF family with potent cardiovascular effects [1,3,5-7 ]. This is the first report of elevated UCN levels, more marked in males, in human systolic HF. In addition, UCN levels fell with increasing severity of HF and with age. The source of UCN in plasma is unknown, but mRNA and peptide are predominantly present in heart, brain and gut [1, 5] . UCN expression is increased in human failing myocardium [5] , suggesting this as one possible source. UCN is positively inotropic and decreases peripheral resistance [3, 7] in animals with HF, and prevents necrosis and apoptosis following simulated hypoxia/ischaemia by a mitogen-activated protein kinase-dependent pathway [6] , suggesting possible adaptive and protective roles. UCN administration also leads to diuresis and natriuresis [7] . Our present data suggest an up-regulation of the UCN system in early HF, which may be cardioprotective (an adaptive response) [6] , but failure of the response as HF increases in severity, especially in elderly patients. Whether administration or replacement of UCN in severe HF could be used as a therapy, as has been demonstrated in animal models [7] , remains to be explored in humans. UCN has anti-inflammatory effects [12] and it reduces lipopolysaccharide-induced tumour necrosis factor α release in vivo and in vitro [13] . In contrast, lipopolysaccharide up-regulates thymic UCN and down-regulates splenic UCN expression [14] . The UCN promoter contains both positive and negative regulatory elements, including the cytokine signalling associated CCAAT/enhancer-binding protein [15] . As UCN levels fall with increasing disease severity, this may permit unchecked tumour necrosis factor α expression [16] . The reason for the failure of the UCN response with increasing HF severity is unclear, but may potentially lead to disease progression due to removal of cardioprotective or anti-inflammatory effects. The usual pattern for most hormones is a progressive elevation with HF severity, such as is illustrated by the natriuretic peptides (e.g. N-BNP). Few hormones show a decline with increasing HF severity, but another example is the cardiac hypertrophic factor called myotrophin [17] . It is not known whether some of these specific hormonal responses in HF could be exhausted in the later stages of the disease. A further possibility that remains to be investigated is whether UCN is secreted in response to diastolic dysfunction. Parameters of diastolic dysfunction have not been evaluated in the present study.
Our present finding of improved specificity and ROC AUCs for detection of all HF and particularly in early HF with the combination of UCN and N-BNP in logistic models compared with either peptide alone, is of significance for HF diagnosis. The elevation of UCN, especially in early HF, may be incremental in the diagnostic use of N-BNP. The high negative predictive values for both peptides (especially in the diagnosis of early HF), used individually or in combination, suggests that normal levels would exclude the diagnosis of early HF. However, the incremental value of UCN when considered in combination with N-BNP led to improved positive predictive values and accuracy of diagnosis of early HF. This enhanced specificity would decrease the number of false positive tests and could reduce unnecessary investigation of suspected HF cases.
Conclusions
In summary, plasma UCN is increased in human systolic HF, particularly in males. The UCN response is attenuated with age and with increasing HF severity.
The pathophysiological significance of this finding and the potential for UCN as a marker for early HF require further investigation.
